Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom
    Guideline Concordant Care and New Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom
    Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophilia
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom
    Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease Registry
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology Germany
    Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia Infections
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment Options
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment Options
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Advancing Multidisciplinary Care in Hemophilia
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease China
    BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Improvement of Treatment Environment for Advanced / Recurrent Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Improving RCC Patient Outcomes
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology France, Germany, Italy, Spain, USA, United Kingdom
    Biomarker Testing / Lung Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Employment support / Lung Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Japan
    Immunotherapy in Urothelial Carcinoma
    Release Date:
    Partner: Merck KGaA, Darmstadt, Germany
    Review Process: Pfizer Internal
    Education Oncology All
    Pre-clinical and Translational Research in Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Italy
    Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic Diseases
    Release Date:
    Partner: The Japan College of Rheumatology
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology Japan
    PARP-inhibitor Combination Treatments in Prostate Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Knowledge Gaps in Updated Adult Pneumococcal Immunization Recommendations
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    COVID-19 Vaccine Development for LMICs
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines All
    Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA